Frequently asked questions
This section covers all the questions that we were asked during the OMC. It will be updated regularly with answers to your questions.
Participation in the tendering procedure is open on equal terms to all types of operators from any country, regardless of their geographic location, size or governance structure. However, there is a requirement relating to the place of performance of the R&D services. At least 50% of the total value of activities covered by the framework agreement must be performed in the EU Member States or H2020 associated countries. Therefore, our recommendation would be to ensure that the principal R&D staff working on the PCP is located in the EU Member States or H2020 associated countries.
Yes, the amount mentioned through the OMC events includes VAT, if applicable.
Suppliers from EU member states: Invoicing without VAT using the reverse charge procedure. RJHs full data and VAT number must be included. Suppliers VAT number must appear.
Suppliers from third countries: If the supplier upon import is obliged to report VAT according to the rules of the home country and the invoice contains VAT, that VAT is non-deductible in Sweden. Instead, VAT amount is to be considered as a cost of the service.
The pilot duration will at least be 12 months.
Yes. It will be explained in the Call for Tenders. There is a ceiling per phase:
| PCP Phase I | PCP Phase II | PCP Phase III | |
| Sum contracting budget | €697,500 | €1,395,000 | €2,557,500 |
| Number of suppliers | 5 | 4 | 2 |
| Budget per supplier | €139,500 | €348,750 | €1,278,750€ |
The OMC is running until the end of August. Then, we are going to analyse the learnings and include them in the tender documents. After that, we need the green light of the European Commission (EC) to publish the tender. The EC is not part of the buyers group, but it is co-funding this project under the H2020 programme.
In Phase 3, there is not a winning consortium, at least 2 suppliers will finish Phase 3. If the results of the developed solutions are satisfactory, procurers are open (but not obliged) to search for other mechanisms like a PPI (phase IV) to buy a critical mass of innovative products.
Unfortunately, this is not foreseen due to different health and care systems. The idea is that you develop a comprehensive solution.
In Phase III, the legacy systems would have to be integrated, and they are, obviously, different in each site. Therefore, the solution developed in the PCP should be flexible to be able to adapt to these systems. The purpose of this is that not only the procurers within the buyers’ group are able to use it, but also any other interested procurer in the future (potential customers of your solution). A description will be available in the Call for Tender documents.
In Phase III, data will be available.
Yes.